Although statistical validation of our findings would require analyses of larger sample cohorts, the data from our samples suggest significantly higher LOXL3 fold change gene expression in BRAF+ melanoma than in BRAF– melanoma, dysplastic nevi, and melanoma in situ. The gene discussed is LOXL3; the disease is in situ carcinoma.